You have no items in your shopping cart.

Cart empty

Shop By

Listed in Category: Nervous system

Cerebrolysin 5 ml 5 vials

1 Review(s)

Availability: In Stock



Active substance: Cerebrolysin
Country of origin: Germany/Austria
General description: a Nootropic drug
Product form: 5 ml - vials dark glass (5) - packaging sells contoured (1) - packs of cardboard.

Dosage form

Solution for injection: amber, aquatic, transparent.


a complex of peptides* derived from pig brain 215.2 mg/ml

Excipients: sodium hydroxide, water d/and.

Pharmacological action

Nootropic drug

Cerebrolysin® contains low molecular weight biologically active neuropeptides that penetrate through the BBB and act directly to nerve cells. The drug has organ-specific multimodal action on the brain, i.e., provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: Cerebrolysin® improves the efficiency of aerobic energy metabolism of the brain, improves the intracellular protein synthesis in the developing and aging brain.

Neuroprotective effects: the drug protects neurons from the damaging effect of lactic acidosis, prevents the formation of free radicals, increases berievement and prevents the death of neurons under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).

Neurotrophic activity: drug Cerebrolysin® - the only peptidergic nootropic drug with proven neurotrophic activity similar to the action of natural factors of neuronal growth (NGF), but manifested in the conditions of peripheral administration.

Functional neuromodulation: the drug has a positive effect in disorders of cognitive functions, improves concentration, memory processes.



— Alzheimer's disease;

syndrome of dementia of various Genesis;

chronic cerebrovascular insufficiency;

— ischemic stroke;

— traumatic injuries of brain and spinal cord;

— delay of mental development in children;

— hyperactivity and attention deficit in children;

— endogenous depression resistant to antidepressants (in the complex therapy).


— acute renal failure

— epileptic status;

— hypersensitivity to the drug.


To Top
© 2016-2022
All right reserved.